Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: Effect on cost and adverse events

Canadian Journal of Gastroenterology

Volumn 19, Issue 3, 2005, Pages 147-151

  Sayani, Farzana A ^a   Prosser, Connie ^a   Bailey, Robert J ^a   Jacobs, Philip ^a   Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

6 mercaptopurine; Azathioprine; Crohn's disease; Health economics; Inflammatory bowel disease; Mesalamine; Pharmacoeconomics; Thiopurine methyltransferase (TPMT); Ulcerative colitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; GAMMA GLUTAMYLTRANSFERASE; MESALAZINE; THIOPURINE METHYLTRANSFERASE; TRIACYLGLYCEROL LIPASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLOOD CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; COST CONTROL; CROHN DISEASE; DEMOGRAPHY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVITY; ENZYME ANALYSIS; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEALTH CARE COST; HUMAN; LEG CRAMP; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MYALGIA; NAUSEA AND VOMITING; PANCREATITIS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; ULCERATIVE COLITIS;

EID: 17644381606     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/470863     Document Type: Article

References (25)

1. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39.
2. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2:944-7.
3. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7.
4. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
5. Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105:367-72.
6. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-42.
7. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 1989;111:641-9.
8. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5.
9. Lennard L. Clinical implications of thiopurine methyltransferase-optimization of drug dosage and potential drug interaction. Ther Drug Monit 1998;20:527-31.
10. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
11. Lennard L, Lilleyman JS. Variable 6-mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989;7:1816-23. Erratum in: J Clin Oncol 1990;8:567.
12. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
13. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 2002;16:389-98.
14. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
15. Cuffari C, Theoret Y, Latour S, Seidman G. 6-mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity. Gut 1996;39:401-6. Erratum in: Gut 1998;43:301.
16. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
17. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85:323-33.
18. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49:665-70.
19. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002;51:143-6.
20. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
21. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456-9.
22. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464-75. Erratum in: Clin Pharmacol Ther 2000;67:431.
23. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandbom WJ. Balsalazide and azathioprine or 6-mercaptopurine: Evidence for a potentially serious drug interaction. Gastroenterology 1999;116:1505-6.
24. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol 1996;49:393-6.
25. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: The cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002;29:2507-12.